In addition to having several other responsibi lities, I lead a clinical research group and have designed and implemented, and have been a principal investigator for, numerous investigator initiated and industrysponsored clinical trials. For the most part my group has participated in phase II or III clinical trials, but we have per formed a few phase I studies. I was recently asked to participate in a phase I clinical trial of a new biologic agent for IBD, but have declined for what I believe to be ethical reasons.
Phase I clinical trials usually occur after pilot studies have been completed in animals to deduce the potential mechanisms of action, pharmacology and toxicology of a drug. As such, they are generally the first stage of drug testing in humans. Phase I trials are required and designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a drug in humans. However, unlike phase II or III trials, phase I trials are not intended to demon strate or confirm clinical efficacy. This latter point is extremely important when patients are recruited, as the concept of equipoise regard ing the potential benefit of a therapy is not applicable-there are no preliminary data (and no rationale) available to be able to present an informed risk-benefit statement when obtain ing the consent of a patient to enter the trial. Therefore, phase I clinical trials are usually per formed in normal, healthy individuals or termi nally ill patients. Often, healthy controls are paid to participate in phase I trials in contrast to the volunteers recruited for phase II or III trials Even for phase II trials (and some phase III trials) I am afraid that some patients have been 'burned' by their participation-and not from unexpected toxicity. Instead, with the number of trials of biologic agents increasing, numerous volunteer patients have been immunized against a biologic by their early exposure to it, and have subsequently developed hypersensitivity reac tions and loss of response when reexposed to the same drug once it has been approved for marketing.
I learned a lesson with infliximab, the first biologic agent approved for the treatment of Crohn's disease. In the early (phase II) studies of infliximab, patients in the treat ment groups were exposed to a single infu sion or a series of three infusions of infliximab (N Engl J Med [1997 ] 337: 1029 -1035 N Engl J Med [1999 ] 340: 1398 -1405 . Although such studies demonstrated the remarkable efficacy of infliximab and led to FDA approval, once the studies were completed, patients were unable to obtain any further doses of inflixi mab until it was marketed 6-18 months later. When patients who responded so splendidly (and after a relatively short duration) were reexposed to marketed infliximab, approxi mately 25% developed severe delayed hyper sensitivity reactions that precluded subsequent dosing (Gastroenterology [2003] 124: 1140-1150). Ultimately, these patients were unable to benefit from the drug that they volunteered to test because of the development of anti infliximab antibodies. Furthermore, nearly a decade passed before a second, alternative antiTNF agent-adalimumab-became avail able. These folk were clearly canaries in a mine shaft…and they got the shaft! Consequently, I now have serious concerns regarding enrolling patients into phase I, or even phase II, trials of agents that have the potential to induce the development of antibodies, unless it is clearly stated during 'informed consent' that participating in the clinical trial could preclude them from gaining any benefit from the experimental therapy, even if it is eventually proven to be effective and approved for marketing. 
